PROMISING RESULTS WITH RITUXIMAB IN A CASE OF SEVERE SYSTEMIC ARTHRITIS - JUVENILE IDIOPATHIC ARTHRITIS REFRACTORY TO MULTIPLE DRUGS

N. Iagăru, A.V. Cochino

University of Medicine and Pharmacy "Carol Davila", Pediatric Clinic/Mother and Child Healthcare Institute "Alfred Rusescu" Bucharest

Abstract. Background. Systemic arthritis belongs to a heterogeneous group of pediatric rheumatic diseases known as juvenile idiopathic arthritis (JIA). This subtype is defined by extraarticular signs which, even today, lead to diagnosis without specific lab tests. Patients with systemic arthritis (sJIA) also have a range of other prominent features, including elevation of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), leukocytosis with high neutrophil counts and thrombocytosis. Ferritin concentrations are high and correlate with systemic disease activity. Systemic arthritis is often extraordinarily resistant to treatment with steroids, methotrexate, etanercept, etc. We will present one such case, with persistent evolution refractory to multiple conventional and biological remissive drugs.

Keywords:

Background

Systemic arthritis belongs to a heterogeneous group of pediatric rheumatic diseases known as juvenile idiopathic arthritis (JIA). This subtype is defined by extraarticular signs which, even today, lead to diagnosis without specific lab tests. Patients with systemic arthritis (sJIA) also have a range of other prominent features, including elevation of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), leukocytosis with high neutrophil counts and thrombocytosis. Ferritin concentrations are high and correlate with systemic disease activity. Systemic arthritis is often extraordinarily resistant to treatment with steroids, methotrexate, etanercept, etc. We will present one such case, with persistent evolution refractory to multiple conventional and biological remissive drugs.

Case

D.G., 17 y.o., Caucasian female, rural origin, is admitted to our hospital beginning with 17.05.2005, for longer (even 3 month!) or shorter periods of time (every month since then).

The admission reasons were almost the same every time: fever 39-40.5°C, chills, rash, polyarthritis and malaise.

History. The patient was diagnosed with Systemic Onset -JIA at 9 y.o. (fever, rash, hepatosplenomegaly, pericarditis and oligoarticular arthritis). After 6 months of treatment with prednisone, remission was obtained and it was persistent for 5 years. She relapsed in 07.05.2005 when she came to our hospital with fever (39.5-40.5°C), chills, evanescent rash, polyarthritis, generalized lymphadenopathy, hepatosplenomegaly and progressive malaise.

Personal and family history. Normal data concerning growth and functional milestones. Patho-
logic personal history: Atrial septal defect diagnosed at 9 y.o., spontaneously closed before 14 y.o.

Family history: Mother: 40 y.o.; father: 46 y.o.; 2 healthy brothers; no rheumatic diseases in the family.

Clinic exam after relapsing (17th May 2005): malaise, chills, fever 39.5°C, arthralgias (bilateral knees and ankles) and myalgias; generalized moderate lymphadenopathy and discrete hepatomegaly. One week after admission the patient presents an evanescent maculoerythematous rash on thorax, face, limbs and a facial rash (cheeks, nose bridge). After a month she presents right wrist and left ankle arthritis and then swelling of the 2nd left costochondral junction. Arthralgias become generalized. In evolution she complains of precordial pain which, together with the echographic exam (small amount of liquid in pericardial sac) lead to the diagnosis of pericardial serositis. At the same time, she presented fixed erythematous, hard, tender plaques on the shanks and forearms (next to wrist and ankle joints) different as aspect and persistence (weeks!) from the characteristic rash of systemic arthritis. (Figure 1)

Lab exams. They were constantly characterized, from the beginning of the second evolutive cycle, by an important inflammatory syndrome with ESR of 126 mm/h, CRP 34.5 mg/dL, serum fibrinogen 1000 mg/dL, hyperleukocytosis (25.000-30.600/ mmc) with neutrophilia (80,5%). Thrombocytosis (750.000/mmc) and hyperferritinemia (2294 ng/ml) complete the characteristic features of systemic arthritis.

For differential diagnosis the following tests were performed: blood cultures (sterile), bone marrow exam (reactive bone marrow, no atypia), antinuclear antibodies (ANA) and anti-double-stranded DNA (anti-dsDNA) antibodies (negative), anti-Scl 70 autoantibodies and anti-centromere antibodies (negative), anti-smooth muscle antibodies (negative), muscular enzymes (normal CK), normal transaminases (ALT, AST), HBs antigen, HVC, EBV and HIV antibodies (negative), abdominal ultrasonographic exam (normal).

Rheumatoid Factor (RF) was constantly negative. Cardiac ultrasonography shows small amount of liquid (5mm in the pericardial sac anterior to the right ventricle, 2 mm posterior to the left ventricle). Slit lamp examination of the anterior eye pole was constantly normal.

Periungual capillaroscopy was quasinormal and skin biopsy was slightly suggestive for a possible scleroderma or an infectious process but special stainings deny morphea supposition (These tests were needed because of certain scleroderma-like skin lesions, suggesting a possible JIA/SD overlap syndrome).

Anamnestic, clinic and lab findings confirm the diagnosis of systemic arthritis – second evolutive cycle.

Due to severe and persistent (between 17 May 2005 and 17 March 2006, the patient was in the hospital for 221 days !) articular and, especially, extraarticular symptoms and due to biological inflammatory syndrome, we tried almost every conventional therapeutic schemes and also two biologic agents (Table I).

Evolution

In the 3 years following the relapse, the evolution was catastrophic, despite therapeutic efforts:
high persistent fever, evanescent rash, sclerodermalike plaques for several months in 2006 (Figure 1), hepatosplenomegaly, cachexia (weight loss of 15 kg, from 48kg in 2005 to 33kg in 2007), secondary anemorrhea, severe anemia (Hb=6.8g/dL), hypoalbuminemia (2.1g/dL), osteoporosis (BMD L2-L4=0.744g/cm; Z=3.305g/cm) with loss of T12 and L1 vertebral body height; she had violent radicular pain and she was bedridden in 2006). Her symmetric polyarthritis affected over 30 joints (all big joints, metacarpophalangeal and proximal interphalangeal joints, first left metatarsophalangeal joint, 2nd left costochondral junction, and even the cervical spine). Ankylosis in flexion has gradually developed especially in knees, ankles, wrists, elbows and in the proximal interphalangeal and metacarpophalangeal joints (Figure 3 and 4.) Biologic inflammatory syndrome persisted during all this time with extremely high values (ESR over 100mm/h, CRP over 200-250 mg/L, leukocytes over 20.000/mm with neutrophilia over 75%).

Wrist x-rays examination (after 8 months of evolution): the entire radiocarpal and metacarpal region had remarkable bone demineralization and diminished joint spaces, but with preserved bone integrity. Poznanski index was under 2 SD.

Articular ultrasonography: small amount of intraarticular liquid (knees and wrists). Hence, the walking became very difficult, possible only with support, and attending school was impossible. In June 2008 she was 35 kg weight and 156 cm height (Table II).

<table>
<thead>
<tr>
<th>Date</th>
<th>T (°C)</th>
<th>G (kg)</th>
<th>Joints with active arthritis (Total no.)</th>
<th>Joints with impaired movement (Total no.)</th>
<th>DAS 28 3v</th>
</tr>
</thead>
<tbody>
<tr>
<td>30/01/2008</td>
<td>39.5</td>
<td>33.5</td>
<td>33</td>
<td>33</td>
<td>8.97</td>
</tr>
<tr>
<td>15/02/2008</td>
<td>39.5</td>
<td>34</td>
<td>35</td>
<td>35</td>
<td>9.13</td>
</tr>
<tr>
<td>05/03/2008</td>
<td>39-40</td>
<td>33</td>
<td>35</td>
<td>35</td>
<td>9.20</td>
</tr>
<tr>
<td>09/05/2008</td>
<td>41.5</td>
<td>35</td>
<td>20</td>
<td>22</td>
<td>7.71</td>
</tr>
<tr>
<td>20/06/2008</td>
<td>38</td>
<td>35</td>
<td>20</td>
<td>22</td>
<td>7.14</td>
</tr>
<tr>
<td>14/08/2008</td>
<td>37</td>
<td>38</td>
<td>2</td>
<td>22</td>
<td>5.69</td>
</tr>
</tbody>
</table>

The general aspect revealed a very ill, pale, cachectic, very depressive adolescent female. In June 2008 the CHAQ score was 16 (2), and DAS 28 3v score was 5.69 (Table II). The cardiac ultrasound performed in 2007 showed endocardial calcification on anterior mitral valve and on the
right ventricle moderator band, suggestive for a possible previous endocarditis (Figure 2).

A slight clinic and biologic improvement began in June 2008, 2 months after the second cure with rituximab 1000 mg IV. (Table III). This improvement was not seen after the first two infusions of 500 mg rituximab, previously given, despite the persistent B lymphocytes depletion (<1%).

In the last 3 months the patient received: MTX 10mg/week (the avoidance of high doses was dictated by previous toxic pneumonia), Arava (Leflunomide) 10mg/d, Arcoxia 60mg (Etoricoxib) 1 tb/d, Tardyferon (Ferrous sulfate 80mg) 1tb/d, Rocaltrol 0,25μg (Calcitriol) 2tb/d, Calcium lactate 1,5g/d, Actonel (Risedronate sodium) 5mg/d, Miacalcic (Calcitonin 50ui/ml) 1 vial/week. In the meantime she attends physical and kinesiotherapy programs.

Discussion

Polycyclic evolution of the systemic arthritis involves relapses, sometimes for long periods of time, even years [1]. In these cases the relapses can occur even in adult age. Approximately 34% of the patients can present this evolution type [2]. Our patient’s two periods of disease’s intense activity seem to confirm this type of evolution. The continuous 3 years evolution of the second cycle suggests the persistent type of the disease. The remission definition of the JIA, still under debate, includes, along with absence of medication for 12 months: 1) no fever, rash, adenopathies, hepatosplenomegaly or serositis; 2) absence of active arthritis; 3) ESR and CRP in normal range; 4) the best possible score after doctor’s evaluation [3]. In our case none of these criteria was fulfilled, even though in the last 3 months there was a remarkable improvement (Tables II and III). The probability of the overlap syndrome, suggested by the presence of certain

<table>
<thead>
<tr>
<th>Date</th>
<th>CRP (mg/L)</th>
<th>Hb (g/L)</th>
<th>ESR (mm/h)</th>
<th>Leukocytes (x 10^9/l)</th>
<th>Albumin (g/L)</th>
<th>Ferritine (μg/L)</th>
<th>IgG (g/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>30/01/2008</td>
<td>250.0</td>
<td>96</td>
<td>116</td>
<td>10.87</td>
<td>24</td>
<td>2294</td>
<td>16.34</td>
</tr>
<tr>
<td>15/02/2008</td>
<td>245.0</td>
<td>93</td>
<td>118</td>
<td>8.98</td>
<td>21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>05/03/2008</td>
<td>180.0</td>
<td>84</td>
<td>129</td>
<td>8.01</td>
<td>20</td>
<td>1781</td>
<td>18.18</td>
</tr>
<tr>
<td>23/04/2008</td>
<td>210.2</td>
<td>110</td>
<td>116</td>
<td>10.06</td>
<td>25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09/05/2008</td>
<td>210.2</td>
<td>99</td>
<td>85</td>
<td>9.36</td>
<td>25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20/06/2008</td>
<td>121.5</td>
<td>120</td>
<td>40</td>
<td>11.97</td>
<td>35</td>
<td>932</td>
<td></td>
</tr>
<tr>
<td>14/08/2008</td>
<td>204.0</td>
<td>120</td>
<td>20</td>
<td>7.39</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table III
scleroderma-like skin symptoms, was not confirmed either histopathologically or immunologically (absence of anti-Scl 70 and anticentromere antibodies). Although systemic features (fever, rash, pericarditis), as generally described in field literature, became mild in the first months or years of the disease (2 to 5 years [4]), the absence of remission after such a long time in the biological therapy era (failure of etanercept combined with MTX, and also, infliximab combined with azathioprine) rather suggests a persistent systemic arthritis / JIA (~55% of cases [2]) and “treatment needed for indefinite period of time” [3]. In addition to cytokine blockade, the B-cell-targeted therapy with rituximab, a chimerical anti-CD20 monoclonal antibody, is now successfully used in Rheumatoid Arthritis [6, 7, 8]. We used four rituximab infusions (500 mg on days 1 and 15 for the first series, and 1000 mg for the next two infusions after 6 months, with methylprednisolone 100mg IV, given as pre-medication) to treat this refractory case of systemic arthritis. The remarkable clinical and biological improvement, noticeable 4 months after the second series of rituximab, was very encouraging: ESR, CRP, and DAS 28 had significantly fallen (see Table II and III). Unfortunately, because of the lack of studies and approvals (FDA, EMEA, National Authority for Drugs) we stopped this treatment, although cases successfully treated with rituximab sporadically go on [9, 10, 11]. For the near future, we have two theoretical possibilities: 1) the patient will be included in a tocilizumab treatment protocol [5], which is hoped to have better results, due to the major role of IL-6 in the systemic JIA (but also unapproved yet for JIA); 2) wait for the 18 y.o. of age to legally continue the rituximab treatment recommended by the rheumatologists for adults.

In conclusion, this report of a JIA case refractory to conventional DMARDs and biological agents reflects the limits of our therapeutic means, especially in systemic arthritis. We wait for an imperative fortification of biological antirheumatic arsenal for systemic arthritis through new drugs like tocilizumab, and, why not, rituximab.

References

10. Baildan EM, Saladi S. Rituximab in ANA positive polyarticular juvenile idiopathic arthritis (JIA) with uveitis. Pediatric Rheumatology 2008, 6(suppl):P71(poster presentation)